

Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy

Information for the public

Published: 10 May 2023

www.nice.org.uk

Olaparib (Lynparza), alone or with endocrine therapy, is available on the NHS. It is a possible adjuvant (after surgery) treatment for HER2-negative high-risk early breast cancer that has been treated with chemotherapy before or after surgery in adults with germline BRCA1 or BRCA2 mutations.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on breast cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Breast Cancer Now](#), 0808 800 6000
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5172-7